Добро пожаловать на наш сайт!
Welcome to our website!

NATO ADVANCED STUDY INSTITUTE, 2009
phone + 998 98 126 74 06
skype fargals
email info@fargals.com
NATO ADVANCED STUDY INSTITUTE, 2009
2009-06-6

R.A.Ibadov, L.G.Bajenov, Z.N.Mansurov, Z.A. Shanieva, A.Kh.Babadjanov, E.V.Rizaeva

NEW BIOTECHNOLOGY IN THE PROPHYLAXIS AND COMPLEX TREATMENT OF PURULENT-INFLAMMATORY DISEASES OF THE LUNGS IN PATIENTS WITH LONG-TERM OF ARTIFICIAL VENTILATION OF LUNGS

V.Vakhidov Republican Specialized Center Of Surgery, Tashkent, Uzbekistan

      By the widening of indications to artificial ventilation of lungs (AVL), improving technologies and methods of invasive respiratory support led to the good results on intensive care of some critical conditions. But nowadays it is still top agenda the risks of developing of ventilator-associated pneumonia, angiogenic sepsis, polyorganic insufficiency etc. 

       Purpose of investigation: Investigate activity of the new antibacterial drug "FarGALS" for prophylactics and treatment pyoinflammatory lung disease by patients being in ANL for a long time. Materials of our investigation was results of bacteriologic tests from trachea, mouth, washing material from bronchi of patient on AVL for 2008 year/ this patient was divided in 2 group: 1- patients with FarGALS (1:4); 2- patient with traditional treatment.